Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C6IQ
|
|||
| Former ID |
DIB007068
|
|||
| Drug Name |
Stamulumab
|
|||
| Synonyms |
MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 1/2 | [1] | |
| Company |
Wyeth
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 8 (GDF-8) | Target Info | . | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| WikiPathways | Hypertrophy Model | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00104078) Study Evaluating MYO-029 in Adult Muscular Dystrophy. U.S. National Institutes of Health. | |||
| REF 2 | Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.